While in HNSCC, low expression of IL6 mRNA improves survival of the patients with marginal statistical significance (Figure 3, XENA [44]), in ovarian and breast cancers, there is no difference in survival of the patients with high IL6 expression. This evidence concerns the gene IL6 and breast carcinoma.